Together, these data suggest that RAS stability is differentially regulated in hematologic cancers versus adenocarcinomas and further support the notion that PPP1R2/PP1C/LZTR1-dependent regulation of KRAS stability is a feature of hematologic cancers. The gene discussed is PPP1R2; the disease is hematopoietic and lymphoid cell neoplasm.